| Drug Name |
Levodopa |
| Drug ID |
BADD_D02439 |
| Description |
Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the blood-brain barrier[Label,A177781]. Once past the blood-brain barrier, levodopa is metabolized to dopamine and supplements the low endogenous levels of dopamine to treat symptoms of Parkinson's[Label]. The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133]. |
| Indications and Usage |
For the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication, and manganese intoxication. |
| Marketing Status |
Not Available |
| ATC Code |
N04BA01 |
| DrugBank ID |
DB01235
|
| KEGG ID |
D00059
|
| MeSH ID |
D007980
|
| PubChem ID |
6047
|
| TTD Drug ID |
D08HVR
|
| NDC Product Code |
51846-1052; 51552-1348; 10144-342; 51846-1053; 65977-0126; 62331-013; 49452-2680; 11014-0443; 70600-019; 51927-0049; 64220-199; 58624-0238; 17333-059; 58624-0234 |
| Synonyms |
Levodopa | L-Dopa | L Dopa | 3-Hydroxy-L-tyrosine | 3 Hydroxy L tyrosine | L-3,4-Dihydroxyphenylalanine | L 3,4 Dihydroxyphenylalanine | Levopa | Larodopa | Dopaflex | Dopar |
